zurück

Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamid (new indication: HIV infection, patients aged 2 to < 6 years)

 

Subject:

  • Active Substance: Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamid 
  • Name: Genvoya®
  • Therapeutic area: HIV infection
  • Pharmaceutical company: Gilead Sciences GmbH

 

Time table:

  • Start: 01.11.2022
  • Final decision by G-BA: 20.04.2023

 

Final decision:

  1. Therapy-naive children: No additional benefit proved
  2. Therapy-experienced children: No additional benefit proved